Literature DB >> 10750561

Direct and indirect actions of fibroblast growth factor 2 on osteoclastic bone resorption in cultures.

H Kawaguchi1, D Chikazu, K Nakamura, M Kumegawa, Y Hakeda.   

Abstract

Fibroblast growth factor 2 (FGF-2 or basic FGF) is known to show variable actions on bone formation and bone resorption. This study was undertaken to elucidate the mechanisms whereby FGF-2 affects bone metabolism, especially bone resorption, using three different culture systems. FGF-2 at 10(-9) M and higher concentrations induced osteoclastic cell formation in the coculture system of mouse osteoblastic cells and bone marrow cells, and this induction was abrogated by nonsteroidal anti-inflammatory drugs (NSAIDs). 45Ca release from prelabeled cultured mouse calvariae stimulated by FGF-2 (10(-8) M) was also inhibited by NSAIDs, and the inhibition was stronger by NSAIDs, which are more selective for inhibition of cyclooxygenase 2 (COX-2) than COX-1, suggesting the mediation of COX-2 induction. COX-2 was highly expressed and its messenger RNA (mRNA) level was stimulated by FGF-2 in osteoblastic cells whereas it was undetectable or not stimulated by FGF-2 in cells of osteoclast lineage. To further investigate the direct actions of FGF-2 on osteoclasts, resorbed pit formation was compared between cultures of purified osteoclasts and unfractionated bone cells from rabbit long bones. FGF-2 (> or = 10(-12) M) stimulated resorbed pit formation by purified osteoclasts with a maximum effect of 2.0-fold at 10(-11) M, and no further stimulation was observed at higher concentrations. However, FGF-2 at 10(-9) M - 10(-8) M stimulated resorbed pit formation by unfractionated bone cells up to 9.7-fold. NS-398, a specific COX-2 inhibitor, did not affect the FGF-2 stimulation on purified osteoclasts but inhibited that on unfractionated bone cells. We conclude that FGF-2 at low concentrations (> or =10(-12) M) acts directly on mature osteoclasts to resorb bone moderately, whereas at high concentrations (> or = 10(-9) M) it acts on osteoblastic cells to induce COX-2 and stimulates bone resorption potently.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10750561     DOI: 10.1359/jbmr.2000.15.3.466

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  12 in total

1.  A common variant in fibroblast growth factor binding protein 1 (FGFBP1) is associated with bone mineral density and influences gene expression in vitro.

Authors:  Nicole Hoppman; John C McLenithan; Daniel J McBride; Haiqing Shen; Jan Bruder; Richard L Bauer; John R Shaffer; Jie Liu; Elizabeth A Streeten; Alan R Shuldiner; Candace M Kammerer; Braxton D Mitchell
Journal:  Bone       Date:  2010-05-05       Impact factor: 4.398

2.  The investigation of synovial genomic targets of bucillamine with microarray technique.

Authors:  Kenji Oki; Fumio Tsuji; Koji Ohashi; Masaaki Kageyama; Hiroyuki Aono; Minoru Sasano
Journal:  Inflamm Res       Date:  2009-03-17       Impact factor: 4.575

3.  Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis.

Authors:  Nan Su; Qidi Sun; Can Li; Xiumin Lu; Huabing Qi; Siyu Chen; Jing Yang; Xiaolan Du; Ling Zhao; Qifen He; Min Jin; Yue Shen; Di Chen; Lin Chen
Journal:  Hum Mol Genet       Date:  2010-01-06       Impact factor: 6.150

4.  TGF-β in dentin matrix extract induces osteoclastogenesis in vitro.

Authors:  Wannakorn Sriarj; Kazuhiro Aoki; Keiichi Ohya; Mariko Takahashi; Yuzo Takagi; Hitoyata Shimokawa
Journal:  Odontology       Date:  2013-12-24       Impact factor: 2.634

5.  Overexpression of H1 calponin in osteoblast lineage cells leads to a decrease in bone mass by disrupting osteoblast function and promoting osteoclast formation.

Authors:  Nan Su; Maomao Chen; Siyu Chen; Can Li; Yangli Xie; Ying Zhu; Yaozong Zhang; Ling Zhao; Qifen He; Xiaolan Du; Di Chen; Lin Chen
Journal:  J Bone Miner Res       Date:  2013-03       Impact factor: 6.741

6.  Angiotensin II reduces calcium uptake into bone.

Authors:  Scott J Schurman; William H Bergstrom; Lawrence R Shoemaker; Thomas R Welch
Journal:  Pediatr Nephrol       Date:  2003-11-25       Impact factor: 3.714

Review 7.  Fibroblast growth factor signaling in skeletal development and disease.

Authors:  David M Ornitz; Pierre J Marie
Journal:  Genes Dev       Date:  2015-07-15       Impact factor: 11.361

8.  Bone regeneration by the combined use of tetrapod-shaped calcium phosphate granules with basic fibroblast growth factor-binding ion complex gel in canine segmental radial defects.

Authors:  Muneki Honnami; Sungjin Choi; I-li Liu; Wataru Kamimura; Tetsushi Taguchi; Hironori Hojo; Nobuyuki Shimohata; Shinsuke Ohba; Hiroyuki Koyama; Ryohei Nishimura; Ung-il Chung; Nobuo Sasaki; Manabu Mochizuki
Journal:  J Vet Med Sci       Date:  2014-03-26       Impact factor: 1.267

9.  Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain.

Authors:  Ling Jin; Yosuke Nonaka; Shin Miyakawa; Masatoshi Fujiwara; Yoshikazu Nakamura
Journal:  Mol Ther       Date:  2016-08-10       Impact factor: 11.454

10.  Opposing effects of Sca-1(+) cell-based systemic FGF2 gene transfer strategy on lumbar versus caudal vertebrae in the mouse.

Authors:  K-H W Lau; S-T Chen; X Wang; S Mohan; J E Wergedal; C Kesavan; A K Srivastava; D S Gridley; S L Hall
Journal:  Gene Ther       Date:  2016-03-02       Impact factor: 4.184

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.